Encompass Health Corporation's Q4 Performance: A Deeper Look into Madison Small Cap Fund's Perspective

Natalie Pace

Financial wellness advocate and author focusing on eco-investing and protecting one's finances.

This report examines the fourth-quarter 2025 performance of Encompass Health Corporation (EHC) as detailed in the Madison Small Cap Fund's investor letter. It highlights the fund's overall challenges and the specific factors influencing EHC's stock, contrasting its defensive attributes with prevailing market sentiment.

Navigating Market Currents: Encompass Health's Q4 Trajectory Amidst Shifting Investor Preferences

Madison Small Cap Fund's Q4 2025 Performance Review

Madison Investments, a prominent investment advisory firm, recently released its investor letter for the fourth quarter of 2025, specifically for its Madison Small Cap Fund. The report indicated a challenging period for the fund, as it continued to underperform against its benchmark, the Russell 2000 Index. During this quarter, the fund's Class I shares recorded a return of -0.4%, notably trailing the benchmark's 2.2% gain. This underperformance was significantly attributed to sector allocation decisions, with the healthcare sector emerging as the weakest link within the fund's portfolio.

Encompass Health Corporation: A Detailed Financial Overview

Within its detailed fourth-quarter 2025 investor letter, the Madison Small Cap Fund specifically highlighted Encompass Health Corporation (NYSE: EHC). Encompass Health Corporation is recognized as a leader in providing inpatient rehabilitation services. As of March 13, 2026, the company's stock closed at $100.37 per share. Over the preceding month, EHC experienced an 8.87% decline, though its shares had gained 2.68% over the past 52 weeks. The company's market capitalization stood at $10.099 billion, reflecting its substantial presence in the healthcare market.

Healthcare Sector's Impact and EHC's Defensive Stance

The Madison Small Cap Fund's letter elaborated on the healthcare sector's role as the poorest performing sector for the quarter. This downturn was largely driven by the lackluster performance of Encompass Health Corporation (NYSE: EHC), which represented the fund's largest investment position. The fund noted that despite EHC's solid underlying fundamentals, its business model and stock characteristics are inherently defensive. This defensive nature proved to be a disadvantage in a market environment that increasingly favored more aggressive, "offensive" investment strategies, a theme the fund explored further in its letter.

EHC's Position Among Hedge Funds and Future Market Outlook

Despite its significant role in the healthcare industry, Encompass Health Corporation (NYSE: EHC) did not feature on the list of the 40 most popular stocks among hedge funds heading into 2026. While Madison Small Cap Fund recognizes EHC's investment potential, the analysis suggests that other AI-focused stocks might offer superior upside with reduced downside risks. The fund expressed a cautious optimism regarding the speculative market's potential loss of momentum, while acknowledging the unpredictable nature of market irrationality. As of the end of the fourth quarter, approximately 50 hedge fund portfolios held positions in Encompass Health Corporation, consistent with the previous quarter's figures.

you may like

youmaylikeicon
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial

Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial

By Natalie Pace
Teradyne's Strong Market Performance Outshines Dow Jones

Teradyne's Strong Market Performance Outshines Dow Jones

By Natalie Pace
Top CD Annual Percentage Yields for March 2026

Top CD Annual Percentage Yields for March 2026

By Mr. Money Mustache
Urgently Inc. Experiences Remarkable Premarket Surge Amidst Acquisition News and Robust Earnings

Urgently Inc. Experiences Remarkable Premarket Surge Amidst Acquisition News and Robust Earnings

By JL Collins
Weyerhaeuser's Stock Performance: An Analysis of Underperformance in the Real Estate Sector

Weyerhaeuser's Stock Performance: An Analysis of Underperformance in the Real Estate Sector

By T. Harv Eker
Hewlett Packard Enterprise (HPE) Performance Analysis Against Dow Jones

Hewlett Packard Enterprise (HPE) Performance Analysis Against Dow Jones

By Dave Ramsey
Maximizing Your Savings: Top High-Yield Interest Rates Available Today

Maximizing Your Savings: Top High-Yield Interest Rates Available Today

By Natalie Pace
Adobe Faces $150 Million Settlement Over Subscription Practices

Adobe Faces $150 Million Settlement Over Subscription Practices

By Chika Uwazie
Top CD Interest Rates on March 15, 2026: Secure Up to 4.1% APY

Top CD Interest Rates on March 15, 2026: Secure Up to 4.1% APY

By JL Collins
Analyzing XRP's Investment Potential Below $1.50

Analyzing XRP's Investment Potential Below $1.50

By Vicki Robin
Rollins' Stock Performance Versus the S&P 500

Rollins' Stock Performance Versus the S&P 500

By Bola Sokunbi
Abbott Laboratories Introduces Advanced XIENCE Skypoint Stent in India for Enhanced Cardiovascular Care

Abbott Laboratories Introduces Advanced XIENCE Skypoint Stent in India for Enhanced Cardiovascular Care

By T. Harv Eker
Thermo Fisher Scientific Eyes Future Expansion Driven by AI and Strategic Acquisitions

Thermo Fisher Scientific Eyes Future Expansion Driven by AI and Strategic Acquisitions

By Mr. Money Mustache
Jeff Bezos's Strategic Guide to Decision-Making: Two Key Questions for Business Leaders

Jeff Bezos's Strategic Guide to Decision-Making: Two Key Questions for Business Leaders

By Chika Uwazie
Pfizer's New Antibody Drug Shows Promising Results in Atopic Dermatitis Trial

Pfizer's New Antibody Drug Shows Promising Results in Atopic Dermatitis Trial

By Chika Uwazie